What does HPV vaccination mean for gynecologic cancer screening?;Was bedeutet die HPV-impfung für die gynäkologische krebsvorsorge?

Hautarzt

Volumn 58, Issue 6, 2007, Pages 501-506

  Petry, K U ^a  

^a Frauenklinik   (Germany)

Author keywords

Cancer screening program; Cervical carcinoma; Gynecological cancer screening; HPV infection; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ANUS TUMOR; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; GYNECOLOGIC CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MALIGNANT TRANSFORMATION; UTERINE CERVIX CANCER; VACCINATION; VAGINA TUMOR; VIRUS LIKE AGENT; VIRUS VIRULENCE; VULVA TUMOR;

FEMALE; GERMANY; GYNECOLOGY; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; UTERINE CERVICAL NEOPLASMS;

EID: 34250354802     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-007-1340-y     Document Type: Article

References (21)

1. Dürst M, Gissmann L, Ikenberg H, Hausen H zur (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80: 3812-3815
2. Boshart M, Gissmann L, Ikenberg H et al. (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cells derived from cervical cancer. EMBO J 3: 1151-1157
3. Walboomers JMM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
4. Munoz N, Bosch FX, Sanjosé S de et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
5. Ho GYF, Bierman R, Beardsley L et al. (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428
6. Ho GYF, Burk RD, Klein S et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365-1371
7. Hildesheim A, Hadjmichael O, Schwartz P et al. (1999) Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol 180: 571-577
8. Hausen H zur (2003) Impfungen zur Prävention und Therapie von Krebs. HPV 2003 Konferenz, Mai 2003 Theater am Aegi Hannover Germany. Ref Type: Personal Communication
9. Macgregor JE, Campbell MK, Mann EMF, Swanson KY (1994) Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasisve disease. BMJ 308: 1407-1411
10. Chao A, Becker TM, Jordan SW et al. (1996) Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States). Cancer Causes Control 7: 205-213
11. Clavel C, Masure M, Bory JP et al. (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84: 1616-1623
12. Petry KU, Menton S, Menton M et al. (2003) Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88: 1570-1577
13. Petry KU, Menton M, Böhmer G, Iftner T (2001) Die deutschen HPV Screeningstudien. In: Petry KU, Ikenberg H (Hrsg) 44(HPV 2001 - Neue Perspektiven - Neue Standards). Senden F, Waldmann GmbH. Edn Medizin & Wissenschaft. Ref Type: Conference Proceeding
14. Schneider A, Hoyer H, Lotz B et al. (2000) Screening for high-grade cervical intraepithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89: 529-534
15. Koutsky LA, Ault KA, Wheeler CM et al. (2002) A Controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651
16. Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255
17. Ault K (2005) Prophylactic use of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) Risk. ECCO and Paris 2005. Ref Type: Personal Communication
18. Petry KU (2005) Results of EC-funded follow-up studies of the.,HPVCCS" trial. Hannover/Germany. 2nd European conference on cervical cancer screening and Tübingen 19-20 Sep 2005. Ref Type: Personal Communication
19. Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. (2006) Obstetrics outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367: 489-498
20. Brummer O, Hollwitz B, Böhmer G et al. (2006) Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol 102: 517-522
21. Petry KU, Böhmer G, Iftner T et al. (2002) Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol 186: 28-34